You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 16, 2024

Investigational Drug Information for MT-7117


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug MT-7117?

MT-7117 is an investigational drug.

There have been 12 clinical trials for MT-7117. The most recent clinical trial was a Phase 2 trial, which was initiated on December 11th 2023.

The most common disease conditions in clinical trials are Protoporphyria, Erythropoietic, Sclerosis, and Scleroderma, Systemic. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Development America, Inc., Mitsubishi Tanabe Pharma Corporation, and Mitsubishi Tanabe Pharma America Inc.

Recent Clinical Trials for MT-7117
TitleSponsorPhase
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLPMitsubishi Tanabe Pharma America Inc.Phase 3
Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy SubjectsMitsubishi Tanabe Pharma Development America, Inc.Phase 1
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Mitsubishi Tanabe Pharma Development America, Inc.Phase 3

See all MT-7117 clinical trials

Clinical Trial Summary for MT-7117

Top disease conditions for MT-7117
Top clinical trial sponsors for MT-7117

See all MT-7117 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.